Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel
18 Januar 2019 - 1:27AM
Dow Jones News
By Josh Beckerman
A diabetes drug being developed by Sanofi (SNY) and Lexicon
Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food
and Drug Administration advisory panel.
Before the 8-8 vote, Lexicon shares had been halted all day.
The FDA isn't required to follow the advice of such advisory
panels, but it generally does so. An FDA decision is expected by
March 22.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 17, 2019 19:12 ET (00:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
